Is Eli Lilly's Management Charting the Right Course?

In the following video, Motley Fool healthcare analyst David Williamson takes a look at Eli Lilly's (NYSE: LLY  )  CEO, John Lechleiter, examining both how his background as a scientist makes him an a rarity in big pharma and highlighting his rise to the top of Eli Lilly. David then tells investors why Lechleiter's background is both a strength for the company -- and a potential weakness.

Is Eli Lilly a buy or sell?
With two of its top three drugs poised to lose patent protection this year, is Eli Lilly a dividend stock headed nowhere fast? In a new premium report, The Motley Fool's senior pharmaceuticals analyst breaks down all of Lilly's moving parts, including an in-depth analysis of the company's must-know opportunities and reasons to buy and sell today. To find out more click here to claim your copy today.


Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On March 24, 2013, at 11:15 AM, DannyHaszard wrote:

    Generic Zyprexa (Olanzapine) still a cash cow.

    There is a case to be made that the drug companies like Eli Lilly,knew exactly what they were doing to off-label Zyprexa.Zyprexa made them $70 billion dollars they paid no more than $4 billion in fines and lawsuits.-Daniel Haszard Zyprexa victim advocate.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2327944, ~/Articles/ArticleHandler.aspx, 11/27/2014 6:10:11 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement